Evidence map›Paper›PMID 34439390›Full record

ArticleCancers2021

Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study.

Alessandro Ottaiano, Angela Petito, Mariachiara Santorsola, Valerio Gigantino, Maurizio Capuozzo, Daniela Fontanella, Rossella Di Franco, Valentina Borzillo, Sergio Buonopane, Vincenzo Ravo and 28 more

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Immunotherapy Assessment: A New Paradigm for Radiologists.Diagnostics (Basel, Switzerland) · 2023
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Alessandro OttaianoSSD-Innovative Therapies for Abdominal Metastases Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.ORCID 0000-0002-2901-3855
Angela PetitoRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Mariachiara SantorsolaSSD-Innovative Therapies for Abdominal Metastases Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Valerio GigantinoInnovalab Scarl, Molecular Biology, Centro Direzionale, Isola A2, 80143 Naples, Italy.ORCID 0000-0003-0793-7704
Maurizio CapuozzoInnovalab Scarl, Molecular Biology, Centro Direzionale, Isola A2, 80143 Naples, Italy.
Daniela FontanellaInnovalab Scarl, Molecular Biology, Centro Direzionale, Isola A2, 80143 Naples, Italy.
Rossella Di FrancoRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.ORCID 0000-0002-6918-2178
Valentina BorzilloRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Sergio BuonopaneRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Vincenzo RavoRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.ORCID 0000-0003-1414-7110
Esmeralda ScipillitiRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.ORCID 0000-0003-3896-0392
Giuseppe TotaroRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Marcello SerraRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Gianluca AmetranoRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Roberta PentaOncohaematology Department, A.O.R.N. Santobono-Pausilipon di Napoli, 80123 Naples, Italy.
Fabiana TatangeloPathology Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.ORCID 0000-0002-9943-6079
Giosuè ScognamiglioPathology Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.ORCID 0000-0003-4376-111X
Annabella Di MauroPathology Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.ORCID 0000-0002-9128-3186
Maurizio Di BonitoPathology Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Maria NapolitanoFunctional Genomics, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Stefania ScalaFunctional Genomics, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Giuseppina ReaFunctional Genomics, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Sara SantagataFunctional Genomics, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Angela LombardiDepartment of Precision Medicine, University of Campania "L. Vanvitelli", via de Crecchio 7, 80138 Naples, Italy.
Anna GrimaldiDepartment of Precision Medicine, University of Campania "L. Vanvitelli", via de Crecchio 7, 80138 Naples, Italy.
Carlo CaputoDepartment of Precision Medicine, University of Campania "L. Vanvitelli", via de Crecchio 7, 80138 Naples, Italy.
Anna CrispoEpidemiology and Biostatistics Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.ORCID 0000-0002-8455-3328
Egidio CelentanoEpidemiology and Biostatistics Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Gianfranco De FeoScientific Directorate, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Luisa CircelliAMES, Centro Polidiagnostico Strumentale srl, 80013 Naples, Italy.
Giovanni SavareseAMES, Centro Polidiagnostico Strumentale srl, 80013 Naples, Italy.
Raffaella RuggieroAMES, Centro Polidiagnostico Strumentale srl, 80013 Naples, Italy.
Francesco PerriHead&Neck Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.ORCID 0000-0001-8158-7509
Vincenza GranataRadiology Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Gerardo BottiScientific Directorate, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Michele CaragliaDepartment of Precision Medicine, University of Campania "L. Vanvitelli", via de Crecchio 7, 80138 Naples, Italy.ORCID 0000-0003-2408-6091
Guglielmo NastiSSD-Innovative Therapies for Abdominal Metastases Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.
Paolo MutoRadiotherapy Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", via M. Semmola, 80131 Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundin recent years, the management of advanced colorectal cancer (CRC) has been greatly improved with integrated strategies including stereotactic radiation therapy (SRT). The administration of SRT has been demonstrated, particularly in oligo-metastatic (om) CRC, to be a safe and effective option. Interestingly, it has been demonstrated that SRT can induce regression of tumors in non-irradiated regions ("abscopal effect") through stimulation of anti-tumor immune effects ("radiation-induced immunity"). We have recently shown that lung-limited omCRC is characterized by regression of tumor clones bearing specific key driver gene mutations.

aimsto assess the genetic evolution on tumor cancer cells induced by SRT in lung-limited omCRC. Secondary objectives included descriptions of the abscopal effect, responses' duration, toxicity, and progression-free survival. A translational research will be performed to evaluate tumor genetic evolution (through liquid biopsies and Next Generation Sequencing), HLA class I repertoire, peripheral immune cells, and cytokine dynamics.

methodsPRELUDE-1 is a prospective translational study. SRT will be administered only to the largest nodule (with a maximum diameter ≤ 25 mm) in omCRC with two or three radiologically evident lesions. The sample size is based on the innovative hypothesis that radiation-induced immunity could induce regression of tumor clones bearing KRAS oncogene mutations. According to the binomial test, considering the frequency of KRAS mutations and assuming a probability of mutant KRAS→wild type KRAS of p

Indexed as

abscopal effectcolorectal cancerKRASlung metastasesstereotactic radiation therapy

Identifiers

PMID34439390
PMCPMC8394588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.